Gemtuzumab ozogamicin (Mylotarg) has therapeutic activity against CD33 acute lymphoblastic leukaemias in vitro and in vivo. [electronic resource]
Producer: 20050302Description: 310-7 p. digitalISSN:- 0007-1048
- Aminoglycosides -- therapeutic use
- Animals
- Antibodies, Monoclonal -- therapeutic use
- Antibodies, Monoclonal, Humanized
- Antigens, CD -- analysis
- Antigens, Differentiation, Myelomonocytic -- analysis
- Cell Death -- drug effects
- Female
- Gemtuzumab
- Humans
- Immunophenotyping
- Immunotoxins -- therapeutic use
- Mice
- Mice, SCID
- Neoplasm Transplantation
- Precursor Cell Lymphoblastic Leukemia-Lymphoma -- drug therapy
- Sialic Acid Binding Ig-like Lectin 3
- Transplantation, Heterologous
- Tumor Cells, Cultured
No physical items for this record
Publication Type: Journal Article; Research Support, Non-U.S. Gov't
There are no comments on this title.
Log in to your account to post a comment.